Vincristine sulfate (Synonyms: 硫酸長春新堿; Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate)

目錄號: HY-N0488 純度: 99.81%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Vincristine sulfate是一種抗腫瘤長春花生物堿，抑制有絲分裂紡錘體中的 microtubule 形成，導致中期階段的分裂細胞停滯。它與 microtubule 結(jié)合的 K_i 為85 nM。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

Vincristine sulfate Chemical Structure

CAS No. : 2068-78-2

1. 客戶無需承擔相應的運輸費用。

2. 同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥616	In-stock
5 mg	￥350	In-stock
10 mg	￥560	In-stock
50 mg	￥2102	In-stock
100 mg	￥3412	In-stock
200 mg	現(xiàn)貨	詢價
500 mg		詢價
1 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

Other Forms of Vincristine sulfate:

MCE 顧客使用本產(chǎn)品發(fā)表的 51 篇科研文獻

•Cell. 2024 Apr 25;187(9):2288-2304.e27. [Abstract]
•Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
•DRUG RESIST UPDATE. 2023 Feb 13;68:100951.
•Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]
•Cancer Commun (Lond). 2024 Apr;44(4):469-490. [Abstract]
•J Clin Invest. 2024 Mar 7:e172716. [Abstract]

•Cell Rep Med. 2024 Mar 19;5(3):101468. [Abstract]
•Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
•Sci Adv. 2023 Feb 10;9(6):eade9238. [Abstract]
•Mol Ther. 2021 Jul 1;S1525-0016(21)00353-1. [Abstract]
•Leukemia. 2021 Mar 29. [Abstract]
•Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2208457119. [Abstract]
•Br J Cancer. 2024 Aug 22. [Abstract]
•PLoS Biol. 2024 June 27.
•Cell Commun Signal. 2024 Jun 13;22(1):325. [Abstract]
•Acta Pharmacol Sin. 2024 Jun 6. [Abstract]
•Pharmacol Res. 2024 May 9:204:107208. [Abstract]
•Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8. [Abstract]
•Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
•J Transl Med. 2023 Jan 9;21(1):9. [Abstract]
•Biomed Pharmacother. 2020 May;125:110003. [Abstract]
•Int J Biol Macromol. 2019 Jan 30;128:574-582. [Abstract]
•Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [Abstract]
•Front Oncol. 2024 Jul 19:14:1440650. [Abstract]
•J Biomed Inform. 2023 May 15;104383. [Abstract]
•Mol Pharm. 2022 Oct 21. [Abstract]
•Cancers (Basel). 2022 Oct 19;14(20):5127. [Abstract]
•Front Pharmacol. 15 July 2022.
•Cancers (Basel). 2021, 13(13), 3323.
•Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. [Abstract]
•Front Oncol. 2021 Apr 22;11:665763. [Abstract]
•Front Oncol. 2021 Apr 6.
•Front Oncol. 2020 Mar 13;10:308. [Abstract]
•Sci Rep. 2019 Aug 12;9(1):11677. [Abstract]
•Front Microbiol. 2019 May 9;10:939. [Abstract]
•Eur J Med Chem. 2018 Feb 25;146:157-170. [Abstract]
•SLAS Discov. 2024 Feb 12;29(2):100147. [Abstract]
•Biochem Biophys Res Commun. 2023 Jun 27;674:27-35. [Abstract]
•Breast Cancer Res Treat. 2023 May 19. [Abstract]
•J Chromatogr B. 2021, 122591.
•Hum Exp Toxicol. 2021 Feb 4;960327121991901. [Abstract]
•Leuk Lymphoma. 2020 Feb;61(2):420-428. [Abstract]
•Neurobiol Learn Mem. 2019 Sep;163:107038. [Abstract]
•bioRxiv. 2024 July 04.
•bioRxiv. 2023 Sep 16.
•bioRxiv. 2023 Jul 25.
•bioRxiv. 2023 Jun 3.
•bioRxiv. 2023 Apr 14.
•bioRxiv. 2023 Feb 27.
•bioRxiv. 2019 Dec.
•Oncotarget. 2017 Dec 2;8(68):112313-112329. [Abstract]

: Vincristine sulfate purchased from MCE. Usage Cited in: Int J Biol Macromol. 2019 Jan 30;128:574-582. [Abstract]; SGC7901/DDP or SGC7901/VCR cells are transfectedwith si-Con or si-ERK, and transfection efficiency is evaluated by western blot assay at 48 h post transfection.

Vincristine sulfate 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

生物活性
實驗參考方法
純度 & 產(chǎn)品資料
參考文獻

生物活性

Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a K_i of 85 nM.

細胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	171.5 nM Compound: Vincristine sulphate	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28038323]
A549	IC₅₀	20 nM Compound: Vincristine sulfate	Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay	[PMID: 23215348]
BT-549	IC₅₀	54.72 nM Compound: Vincristine sulphate	Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay	[PMID: 28038323]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Cytotoxicity against human colon cancer cells after 48 hrs Cytotoxicity against human colon cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.1 μM Compound: vincristine sulfate	Growth inhibition of human colon cancer cells after 48 hrs Growth inhibition of human colon cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human colon cancer cell by NCI-CLS assay Growth inhibition of human colon cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human CNS cancer cell by NCI-CLS assay Growth inhibition of human CNS cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human prostate cancer cell by NCI-CLS assay Growth inhibition of human prostate cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.13 μM Compound: Vincristine sulfate	Cytotoxicity against human prostate cancer cells after 48 hrs Cytotoxicity against human prostate cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.13 μM Compound: Vincristine sulfate	Cytotoxicity against human CNS cancer cells after 48 hrs Cytotoxicity against human CNS cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Cytotoxicity against human CNS cancer cells after 48 hrs Cytotoxicity against human CNS cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Cytotoxicity against human prostate cancer cells after 48 hrs Cytotoxicity against human prostate cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Growth inhibition of human CNS cancer cells after 48 hrs Growth inhibition of human CNS cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Growth inhibition of human prostate cancer cells after 48 hrs Growth inhibition of human prostate cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human ovarian cancer cell by NCI-CLS assay Growth inhibition of human ovarian cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human renal cancer cell by NCI-CLS assay Growth inhibition of human renal cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human breast cancer cell by NCI-CLS assay Growth inhibition of human breast cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human ovarian cancer cells after 48 hrs Cytotoxicity against human ovarian cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human renal cancer cells after 48 hrs Cytotoxicity against human renal cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human breast cancer cells after 48 hrs Cytotoxicity against human breast cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human ovarian cancer cells after 48 hrs Cytotoxicity against human ovarian cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human renal cancer cells after 48 hrs Cytotoxicity against human renal cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human breast cancer cells after 48 hrs Cytotoxicity against human breast cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human Ovarian cancer cells after 48 hrs Growth inhibition of human Ovarian cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human renal cancer cells after 48 hrs Growth inhibition of human renal cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human breast cancer cells after 48 hrs Growth inhibition of human breast cancer cells after 48 hrs	[PMID: 20684599]
DU-145	IC₅₀	71.83 μM Compound: Vincristine sulphate	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
DU-145	IC₅₀	72.3 nM Compound: Vincristine sulphate	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 28038323]
HEK293	IC₅₀	31 nM Compound: Vincristine sulfate	Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay	[PMID: 23215348]
HeLa	IC₅₀	0.0358 μM Compound: Vincristine sulfate	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
HeLa	IC₅₀	36 nM Compound: Vincristine sulfate	Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay	[PMID: 23215348]
HepG2	IC₅₀	0.69 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 26522953]
HL-60	IC₅₀	11.2 μg/mL Compound: vincristine sulfate	Cytotoxicity against human HL60 cells after 48 hrs Cytotoxicity against human HL60 cells after 48 hrs	[PMID: 17432904]
KB	IC₅₀	0.02 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 26522953]
L02	IC₅₀	28.4 μg/mL Compound: vincristine sulfate	Cytotoxicity against human L02 cells after 48 hrs Cytotoxicity against human L02 cells after 48 hrs	[PMID: 17432904]
Leukemia cell	GI₅₀	0.1 μM Compound: Vincristine sulfate	Cytotoxicity against human leukemia cells after 48 hrs Cytotoxicity against human leukemia cells after 48 hrs	[PMID: 24747749]
Leukemia cell	GI₅₀	0.1 μM Compound: vincristine sulfate	Cytotoxicity against human leukemia cells after 48 hrs Cytotoxicity against human leukemia cells after 48 hrs	[PMID: 22283430]
Leukemia cell	GI₅₀	0.1 μM Compound: vincristine sulfate	Growth inhibition of human leukemia cells after 48 hrs Growth inhibition of human leukemia cells after 48 hrs	[PMID: 20684599]
Leukemia cell	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human leukemia cell by NCI-CLS assay Growth inhibition of human leukemia cell by NCI-CLS assay	[PMID: 20395150]
LNCaP	IC₅₀	0.0029 μM Compound: Vincristine sulphate	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay	[PMID: 20732809]
LNCaP	IC₅₀	6.1 nM Compound: Vincristine sulfate	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay	[PMID: 23215348]
Lu1	IC₅₀	0.48 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay	[PMID: 26522953]
MCF7	IC₅₀	0.51 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 26522953]
MDA-MB-231	IC₅₀	116.6 nM Compound: Vincristine sulphate	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28038323]
Melanoma cell	GI₅₀	0.16 μM Compound: Vincristine sulfate	Cytotoxicity against human melanoma cells after 48 hrs Cytotoxicity against human melanoma cells after 48 hrs	[PMID: 24747749]
Melanoma cell	GI₅₀	0.16 μM Compound: vincristine sulfate	Cytotoxicity against human melanoma cells after 48 hrs Cytotoxicity against human melanoma cells after 48 hrs	[PMID: 22283430]
Melanoma cell	GI₅₀	0.16 μM Compound: vincristine sulfate	Growth inhibition of human melanoma cells after 48 hrs Growth inhibition of human melanoma cells after 48 hrs	[PMID: 20684599]
Melanoma cell	GI₅₀	0.2 μM Compound: Vincristine sulfate	Growth inhibition of human melanoma cell by NCI-CLS assay Growth inhibition of human melanoma cell by NCI-CLS assay	[PMID: 20395150]
NFF	IC₅₀	0.0169 μM Compound: Vincristine sulfate	Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
NFF	IC₅₀	17 nM Compound: Vincristine sulfate	Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay	[PMID: 23215348]
NSCLC	GI₅₀	0.2 μM Compound: Vincristine sulfate	Growth inhibition of human NSCLC cell by NCI-CLS assay Growth inhibition of human NSCLC cell by NCI-CLS assay	[PMID: 20395150]
NSCLC	GI₅₀	0.25 μM Compound: Vincristine sulfate	Cytotoxicity against human NSCLC cells after 48 hrs Cytotoxicity against human NSCLC cells after 48 hrs	[PMID: 24747749]
NSCLC	GI₅₀	0.25 μM Compound: vincristine sulfate	Cytotoxicity against human NSCLC cells after 48 hrs Cytotoxicity against human NSCLC cells after 48 hrs	[PMID: 22283430]
NSCLC	GI₅₀	0.25 μM Compound: vincristine sulfate	Growth inhibition of human NSCLC cells after 48 hrs Growth inhibition of human NSCLC cells after 48 hrs	[PMID: 20684599]
PC-3	IC₅₀	0.011 μM Compound: Vincristine sulphate	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 20732809]
PC-3	IC₅₀	0.0153 μM Compound: Vincristine sulfate	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
PC-3	IC₅₀	15 nM Compound: Vincristine sulfate	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 23215348]
PC-3	IC₅₀	27.6 nM Compound: Vincristine sulphate	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28038323]
PC-3	IC₅₀	28.11 μM Compound: Vincristine sulphate	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
SMMC-7721	IC₅₀	26.7 μg/mL Compound: vincristine sulfate	Cytotoxicity against human SMMC7721 cells after 48 hrs Cytotoxicity against human SMMC7721 cells after 48 hrs	[PMID: 17432904]

體外研究
(In Vitro)

Vincristine sulfate 抑制穩(wěn)態(tài)微管組裝末端微管蛋白二聚體的凈增加，K_i 為 85 nM^[1]。Vincristine sulfate 穩(wěn)定紡錘體，導致染色體無法分離，從而導致中期停滯和低濃度有絲分裂抑制。在較高濃度下，Vincristine sulfate 可能會破壞并誘導微管完全解聚^[2]。Vincristine sulfate 誘導腫瘤細胞凋亡并抑制 SH-SY5Y 細胞增殖，IC₅₀ 為 0.1 μM。Vincristine sulfate 誘導有絲分裂停滯并促進 caspase-3 和 -9 及細胞周期蛋白 B 的表達，同時降低細胞周期蛋白 D 的表達^[3]。Vincristine sulfate 引起的神經(jīng)毒性是由微管功能干擾引起的，這會導致軸突運輸受阻，從而導致軸突變性^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Vincristine（3 mg/kg，腹腔注射）誘導平均生長延遲 > 120 和 > 52 天，并重新填充 0.06% 和 5% 的分數(shù)，分別在攜帶雙側(cè)皮下異種移植 Rh12 或 Rh18 的小鼠中施用^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

923.04

Formula

C₄₆H₅₈N₄O₁₄S

CAS 號

2068-78-2

性狀

固體

顏色

White to off-white

中文名稱

硫酸長春新堿；硫酸長春醛堿；長春新堿硫化物；長春新堿硫酸鹽

結(jié)構(gòu)分類

初始來源

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性數(shù)據(jù)

細胞實驗：

DMSO 中的溶解度 : 83.33 mg/mL (90.28 mM; 超聲助溶 (<80°C); 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

H₂O 中的溶解度 : 50 mg/mL (54.17 mM; 超聲助溶)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	1.0834 mL	5.4169 mL	10.8338 mL
5 mM	0.2167 mL	1.0834 mL	2.1668 mL
10 mM	0.1083 mL	0.5417 mL	1.0834 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.25 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (2.25 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (2.25 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請依序添加每種溶劑： PBS
Solubility: 100 mg/mL (108.34 mM); 澄清溶液; 超聲助溶 (<60°C)

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

計算結(jié)果

工作液所需濃度 : mg/mL

該產(chǎn)品水溶性佳，請具體參考實測水 / PBS / Saline 中的溶解度數(shù)據(jù)。

您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

純度 & 產(chǎn)品資料

純度: 99.81%

選擇批次：

Data Sheet (658 KB) SDS (644 KB)

COA (304 KB) HNMR (312 KB) LCMS (98 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻

[1]. Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7. [Content Brief]

[2]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87. [Content Brief]

[3]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7. [Content Brief]

[4]. Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000. [Content Brief]

[5]. Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7. [Content Brief]

[6]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [Content Brief]

Cell Assay ^[1]	Cells are plated in 2 mL of medium in 35 mm plates at a concentration of about 5×10⁴?cells/mL and grow for 24 h at 37°C in an atmosphere of 5% CO₂?and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻	[1]. Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7. [Content Brief] [2]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87. [Content Brief] [3]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7. [Content Brief] [4]. Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000. [Content Brief] [5]. Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7. [Content Brief] [6]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [Content Brief]

Cell Assay
^[1]

Cells are plated in 2 mL of medium in 35 mm plates at a concentration of about 5×10⁴?cells/mL and grow for 24 h at 37°C in an atmosphere of 5% CO₂?and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻

[1]. Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7. [Content Brief]

[2]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87. [Content Brief]

[3]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7. [Content Brief]

[4]. Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000. [Content Brief]

[5]. Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7. [Content Brief]

[6]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108. [Content Brief]

Vincristine sulfate 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	1.0834 mL	5.4169 mL	10.8338 mL	27.0844 mL
	5 mM	0.2167 mL	1.0834 mL	2.1668 mL	5.4169 mL
	10 mM	0.1083 mL	0.5417 mL	1.0834 mL	2.7084 mL
	15 mM	0.0722 mL	0.3611 mL	0.7223 mL	1.8056 mL
	20 mM	0.0542 mL	0.2708 mL	0.5417 mL	1.3542 mL
	25 mM	0.0433 mL	0.2167 mL	0.4334 mL	1.0834 mL
	30 mM	0.0361 mL	0.1806 mL	0.3611 mL	0.9028 mL
	40 mM	0.0271 mL	0.1354 mL	0.2708 mL	0.6771 mL
	50 mM	0.0217 mL	0.1083 mL	0.2167 mL	0.5417 mL
DMSO	60 mM	0.0181 mL	0.0903 mL	0.1806 mL	0.4514 mL
DMSO	80 mM	0.0135 mL	0.0677 mL	0.1354 mL	0.3386 mL

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vincristine2068-78-2LeurocristineNSC-6757422-Oxovincaleukoblastine硫酸長春新堿硫酸長春醛堿長春新堿硫化物長春新堿硫酸鹽NSC67574NSC 67574Microtubule/TubulinApoptosisInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學研究或藥證申報的用途提供醫(yī)藥研發(fā)服務，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Vincristine sulfate (Synonyms: 硫酸長春新堿; Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate)

Customer Review

Other Forms of Vincristine sulfate:

MCE 顧客使用本產(chǎn)品發(fā)表的 51 篇科研文獻

Vincristine sulfate 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

生物活性

實驗參考方法

純度 & 產(chǎn)品資料

參考文獻

摩爾計算器

稀釋計算器

Vincristine sulfate 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Vincristine sulfate (Synonyms: 硫酸長春新堿; Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate)

Customer Review

Other Forms of Vincristine sulfate:

Vincristine sulfate 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 51 篇科研文獻

Vincristine sulfate 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

生物活性

實驗參考方法

純度 & 產(chǎn)品資料

參考文獻

Vincristine sulfate 相關(guān)抗體:

摩爾計算器

稀釋計算器

Vincristine sulfate 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z